Applied Therapeutics Inc
APLT0.460USD
+0.020+4.45%
交易中 （美东）报价延迟15分钟
65.17M总市值
亏损市盈率 TTM
关于 Applied Therapeutics Inc 公司
Applied Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发一系列针对已验证的分子靶点的新型候选药物，以治疗高度未满足的医疗需求。该公司的主要候选药物 govorestat 是一种新型中枢神经系统渗透性醛糖还原酶抑制剂 (ARI)，用于治疗中枢神经系统 (CNS) 罕见代谢疾病，包括半乳糖血症、山梨醇脱氢酶 (SORD) 缺乏症和 PMM2-CDG。该公司还在开发一种新型强效 ARI AT-001，用于治疗糖尿病性心肌病 (DbCM)，这是一种致命的心脏纤维化。该公司已完成 I/II 期临床试验，评估 AT-001 对约 120 名 2 型糖尿病患者的疗效，未观察到与药物相关的不良反应或耐受性问题。临床前管线还包括 AT-003，这是一种口服时可穿过眼球后部的 ARI，用于治疗糖尿病视网膜病变。
公司简介
公司代码APLT
公司名称Applied Therapeutics Inc
上市日期May 09, 2019
CEOMr. Leslie D. (Les) Funtleyder
员工数量35
证券类型Ordinary Share
年结日May 09
公司地址545 Fifth Avenue, Suite 1400
城市NEW YORK
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编10017
电话12122209226
网址https://www.appliedtherapeutics.com/
公司代码APLT
上市日期May 09, 2019
CEOMr. Leslie D. (Les) Funtleyder
公司高管
名称
名称/职务
职务
持股
持股变动
Evan Prescott Bailey ,
Evan Prescott Bailey ,
Chief Medical Officer
Chief Medical Officer
841.67K
--
Mr. Leslie D. (Les) Funtleyder
Mr. Leslie D. (Les) Funtleyder
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
560.81K
+36.51%
Ms. Stacy J. Kanter, J.D.
Ms. Stacy J. Kanter, J.D.
Independent Director
Independent Director
119.25K
+10.42%
Mr. Constantine Chinoporos
Mr. Constantine Chinoporos
Chief Operating Officer and Chief Business Officer
Chief Operating Officer and Chief Business Officer
90.19K
-71.94%
Dr. Jay S. Skyler, M.D.
Dr. Jay S. Skyler, M.D.
Independent Director
Independent Director
65.00K
--
Ms. Catherine Thorpe
Ms. Catherine Thorpe
Interim Chief Accounting Officer
Interim Chief Accounting Officer
--
--
Mr. John H. Johnson
Mr. John H. Johnson
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Teena L. Lerner, Ph.D.
Dr. Teena L. Lerner, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Dale Hooks
Mr. Dale Hooks
Chief Commercial Officer
Chief Commercial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Evan Prescott Bailey ,
Evan Prescott Bailey ,
Chief Medical Officer
Chief Medical Officer
841.67K
--
Mr. Leslie D. (Les) Funtleyder
Mr. Leslie D. (Les) Funtleyder
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
560.81K
+36.51%
Ms. Stacy J. Kanter, J.D.
Ms. Stacy J. Kanter, J.D.
Independent Director
Independent Director
119.25K
+10.42%
Mr. Constantine Chinoporos
Mr. Constantine Chinoporos
Chief Operating Officer and Chief Business Officer
Chief Operating Officer and Chief Business Officer
90.19K
-71.94%
Dr. Jay S. Skyler, M.D.
Dr. Jay S. Skyler, M.D.
Independent Director
Independent Director
65.00K
--
Ms. Catherine Thorpe
Ms. Catherine Thorpe
Interim Chief Accounting Officer
Interim Chief Accounting Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月20日 周二
更新时间: 5月20日 周二
持股股东
股东类型
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
11.03%
Vestal Point Capital, LP
8.12%
Propel Bio Management, LLC
7.97%
BlackRock Institutional Trust Company, N.A.
6.33%
Knoll Capital Management, LLC
5.51%
Other
61.04%
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
11.03%
Vestal Point Capital, LP
8.12%
Propel Bio Management, LLC
7.97%
BlackRock Institutional Trust Company, N.A.
6.33%
Knoll Capital Management, LLC
5.51%
Other
61.04%
股东类型
持股股东
占比
Investment Advisor
33.47%
Hedge Fund
18.25%
Investment Advisor/Hedge Fund
15.40%
Venture Capital
11.90%
Individual Investor
5.70%
Research Firm
2.36%
Private Equity
0.61%
Sovereign Wealth Fund
0.17%
Bank and Trust
0.07%
Other
12.06%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
297
124.40M
87.87%
-35.48M
2025Q1
297
123.70M
87.51%
-30.40M
2024Q4
287
131.75M
113.23%
-13.70M
2024Q3
251
128.75M
112.47%
+2.21M
2024Q2
218
117.82M
104.34%
+1.65M
2024Q1
214
107.47M
96.19%
+20.49M
2023Q4
204
75.60M
89.15%
+10.52M
2023Q3
201
57.91M
82.88%
+2.25M
2023Q2
197
52.05M
93.62%
+2.03M
2023Q1
199
42.23M
88.25%
+6.29M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
T. Rowe Price Investment Management, Inc.
15.61M
11.03%
+5.23M
+50.40%
Apr 30, 2025
Vestal Point Capital, LP
11.50M
8.12%
--
--
Mar 31, 2025
Propel Bio Management, LLC
11.29M
7.97%
+1.67M
+17.37%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.96M
6.33%
+266.41K
+3.07%
Mar 31, 2025
Knoll Capital Management, LLC
7.80M
5.51%
+2.00M
+34.48%
Mar 31, 2025
VR Adviser, LLC
5.57M
3.93%
-4.42M
-44.27%
Mar 31, 2025
Alexandria Real Estate Equities, Inc.
5.39M
3.81%
-300.00K
-5.27%
Nov 13, 2024
The Vanguard Group, Inc.
5.89M
4.16%
+358.20K
+6.48%
Mar 31, 2025
Shendelman (Shoshana)
4.72M
3.34%
-567.10K
-10.72%
Aug 14, 2024
Schonfeld Strategic Advisors LLC
4.67M
3.3%
-4.09M
-46.66%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Simplify Propel Opportunities ETF
2.06%
Hypatia Women CEO ETF
0%
ProShares Hedge Replication ETF
0%
iShares Biotechnology ETF
0%
SPDR S&P Biotech ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Humankind US Stock ETF
0%
查看更多
Simplify Propel Opportunities ETF
占比2.06%
Hypatia Women CEO ETF
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Biotechnology ETF
占比0%
SPDR S&P Biotech ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares UltraPro Russell2000
占比0%
iShares Russell 2000 Value ETF
占比0%
Fidelity MSCI Health Care Index ETF
占比0%
Humankind US Stock ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
